On April 16, 2026, the U.S. Court of Appeals for the Federal Circuit reversed the district court’s judgment as a matter of law ...
Hosted on MSN
Teva’s bold pivot is reshaping its future
Growth strategy focus: Teva is evolving into a leading biopharma company by building on its generics base with innovative and biosimilar products. Pipeline milestones: Fast track designations, new ...
TORONTO, Feb. 4, 2026 /CNW/ - Teva Canada Limited (Teva Canada) announced today that Health Canada has approved an expanded indication for Pr AJOVY® (fremanezumab solution for subcutaneous injection) ...
Throughout the year, Teva had momentum in innovative medicines, scaling its global generics and biosimilars portfolio. On the brand side, Teva said it continued to showcase strong performance of its ...
PARSIPPANY, N.J. and TEL AVIV, Israel, Jan. 14, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the ...
Learn more Teva Pharmaceutical Industries (NYSE: TEVA) will unveil its first-quarter results this Wednesday, April 29. Many ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results